Arkolith/Insider Trading/ACUR/Form 4

Wesson Bruce F

DirectorACURA PHARMACEUTICALS, INC (ACUR) · full profile →Form 4 · filed Jan 2, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2024Option exercise(M)38K——830K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 2, 2024Disposed to issuer(D)13K——0
Jan 2, 2024Option exercise(M)38K——13K

Transaction Codes

M
Option exercise / conversion
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-000283) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML